Compare Neurocrine Biosciences Inc (NBIX) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Plug Power Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Plug Power Inc trades at $2.19 (market cap $3.16B). The key difference: Neurocrine Biosciences Inc is far larger — about 5× Plug Power Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | PLUG | |
|---|---|---|
Market Cap | $15.77B | $3.16B |
Sector | Health | Industrials |
52-Week High | $185.50 | $4.14 |
52-Week Low | $123.10 | $1.44 |
Enterprise Value | $15.78B | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Plug Power (PLUG) trades at $2.26, up 4.15% today, but remains in a challenging fundamental position with persistent losses. The company shows modest revenue recovery to $710 million in 2025 but continues to report negative gross margins and substantial net losses. Technical indicators suggest a bullish short-term trend, while analyst sentiment remains divided with a $4.04 consensus price target representing significant upside potential from current levels.
While PLUG offers substantial upside based on analyst targets and growing electrolyzer demand, the investment carries high risk due to ongoing operational losses, negative cash flow, and heavy reliance on financing. The company's turnaround strategy shows early progress but requires sustained execution to achieve profitability amid competitive pressures in the hydrogen sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
